Get the Stockscreener App
0.322
4.17%
-0.014
After Hours:
.31
-0.012
-3.73%
Carisma Therapeutics Inc stock is traded at $0.322, with a volume of 361.30K.
It is down -4.17% in the last 24 hours and down -17.77% over the past month.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
See More
Previous Close:
$0.336
Open:
$0.33
24h Volume:
361.30K
Relative Volume:
0.03
Market Cap:
$13.46M
Revenue:
$20.27M
Net Income/Loss:
$-63.80M
P/E Ratio:
-0.2118
EPS:
-1.52
Net Cash Flow:
$-68.35M
1W Performance:
-18.36%
1M Performance:
-17.77%
6M Performance:
-29.97%
1Y Performance:
-69.91%
1-Day Range:
$0.3069
$0.336
1-Week Range:
$0.3069
$0.39
52-Week Range:
$0.1417
$1.27
Carisma Therapeutics Inc Stock (CARM) Company Profile
Name
Carisma Therapeutics Inc
Sector
Industry
Phone
(267) 491-6422
Address
3675 MARKET STREET, PHILADELPHIA
Compare CARM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CARM
Carisma Therapeutics Inc
|
0.322 | 14.17M | 20.27M | -63.80M | -68.35M | -1.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 43.10B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 33.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Carisma Therapeutics Inc Stock (CARM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-10-24 | Downgrade | BTIG Research | Buy → Neutral |
| Apr-11-24 | Initiated | BTIG Research | Buy |
| Oct-03-23 | Initiated | CapitalOne | Overweight |
| Jul-06-23 | Initiated | Evercore ISI | Outperform |
| May-31-23 | Upgrade | Jefferies | Hold → Buy |
| May-24-23 | Initiated | H.C. Wainwright | Buy |
| Apr-14-23 | Initiated | Robert W. Baird | Outperform |
View All
Carisma Therapeutics Inc Stock (CARM) Latest News
What institutional investors are buying Carisma Therapeutics Inc. stockPre Market Picks With High Returns - jammulinksnews.com
What is the dividend policy of Carisma Therapeutics Inc. stockBest Dividend Tracker For Every Investor - jammulinksnews.com
Carisma Therapeutics Inc. stock daily chart insightsMomentum Based Equity Trading Plans Reviewed - metal.it
Carisma Therapeutics Inc. stock outlook for YEARMarket Momentum and Signal Alerts Suggest Reversal - metal.it
Will Carisma Therapeutics Inc. Benefit From Sector TailwindsBuy Low Sell High Stock Watch Strategy in Focus - metal.it
What makes Carisma Therapeutics Inc. stock price move sharplyValue Investing Picks With Stability Outlined - metal.it
Why Carisma Therapeutics Inc. stock attracts strong analyst attentionInvestment Strategy Designed for Capital Protection - metal.it
Moving Average Crossover Confirms Uptrend in Carisma Therapeutics Inc.Watchlist for Low Risk High Return Stocks Updated - metal.it
Published on: 2025-07-28 21:04:54 - metal.it
Applying big data sentiment scoring on Carisma Therapeutics Inc.AI Volatility Forecast and Risk Monitor - Newser
Carisma Therapeutics Inc. stock outlook for YEAR Short-Term Profit Alert With Entry Forecast - Newser
Does Carisma Therapeutics Inc. stock perform well during market downturnsAchieve breakthrough gains with expert advice - jammulinksnews.com
Why is Carisma Therapeutics Inc. stock attracting strong analyst attentionRapidly growing investment returns - jammulinksnews.com
Carisma Therapeutics Inc. (NASDAQ:CARM) Receives $1.93 Average Target Price from Brokerages - Defense World
How volatile is Carisma Therapeutics Inc. stock compared to the marketInvest confidently with professional market insights - jammulinksnews.com
How many analysts rate Carisma Therapeutics Inc. as a “Buy”Capitalize on emerging growth stocks - jammulinksnews.com
Top Risks to Consider Before Buying Carisma Therapeutics Inc. StockHigh Return Investment Tips - Newser
Has Carisma Therapeutics Inc. Stock Ever Crashed Historical Volatility ReviewFree Popular Stock Recommendations - Newser
Key External Factors That Drive Carisma Therapeutics Inc. Stock Price MovementsQuick Profit Idea Stream - Newser
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CARM, ENZB, HSON, TTNP on Behalf of Shareholders - GlobeNewswire Inc.
How high can Carisma Therapeutics Inc. stock price go in 2025Triple-digit returns - jammulinksnews.com
Published on: 2025-07-25 09:50:28 - PrintWeekIndia
Is Carisma Therapeutics Inc. a good long term investmentFree Real-Time Stock Data - Autocar Professional
Carisma Therapeutics Inc. Stock Analysis and ForecastFree Popular Stock Recommendations - PrintWeekIndia
What analysts say about Carisma Therapeutics Inc. stockExtraordinary market timing - jammulinksnews.com
What drives Carisma Therapeutics Inc. stock priceFree Stock Market Real-Time Monitoring - jammulinksnews.com
Published on: 2025-07-22 17:12:50 - jammulinksnews.com
Carisma Therapeutics Transfers Listing to Nasdaq Capital Market - TipRanks
Carisma Therapeutics Inc Stock (CARM) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):